Bruton Tyrosine Kinase (BTK) Inhibitors in Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia - Episode 5

The Role of Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

A select group of hematologic oncologists participated in a virtual workshop to discuss the role of BTK inhibitors in the treatment of MCL and CLL Led by Kami Maddocks, MD; and Anthony Mato, MD. The expert panel shared insights on the available evidence regarding BTK inhibitors in MCL and CLL, novel treatment approaches, and optimal strategies for combining and sequencing therapies.

EP. 1: Dr. Kumar on Treatment Options for Patients Who Progress on a BTK Inhibitor in MCL
EP. 2: Dr. Lunning on Trials Evaluating BTK Inhibitors in CLL
EP. 3: Dr. Maddocks on the Investigation of Noncovalent BTK Inhibitors in MCL
EP. 4: Dr. Danilov on the Future of BTK Inhibitors in CLL
Now Viewing
EP. 5: The Role of Bruton Tyrosine Kinase Inhibitors in Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma
EP. 6: Dr. Owen on Choosing Between BTK Inhibitors in CLL
EP. 7: Dr. Torka on the Role of Pirtobrutinib in R/R MCL
EP. 8: BTK Inhibitors in MCL and CLL
EP. 9: Dr. Phillips on BTK Inhibitor Selection in MCL

Related Content:

Bruton Tyrosine Kinase (BTK) Inhibitors in Mantle Cell Lymphoma and Chronic Lymphocytic LeukemiaScientific Interchange & Workshop
Best Practices in Treating Early-Stage NSCLC
An Evolving Treatment Paradigm: ADCs in Non–Small Cell Lung Cancer
Expanding Horizons: Antibody-Drug Conjugates in Non–Small Cell Lung Cancer